Summit Therapeutics Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Summit Therapeutics Inc. (SMMT) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $18.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2025-05-01
- Summit Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-03-31 was $18.00K, a 92.41% decline year-over-year.
- Summit Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- Summit Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-03-31 was $237.00K.
- Summit Therapeutics Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-09-30 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month |
|---|---|---|
| 2025-03-31 | $18.00K 10-Q · filed 2025-05-01 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 |
| 2024-03-31 | $237.00K 10-Q · filed 2025-05-01 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |